Tissue factor (TF) is a transmembrane glycoprotein that acts as a receptor for nonactivated and activated factor VII (FVII) and triggers the coagulation cascade. TF plays an important role in hemostasis, but may also have noncoagulation functions in vascular development, angiogenesis, and tumor cell metastasis. In tumor cells, analysis of the role of TF has been hampered by the lack of purified TF. In this study, TF
antigen was identified on human A375 malignant melanoma cells using flow cytometry. We further purified TF apoprotein 2.000-fold to homogeneity from A375 melanoma cells using immunoaffinity chromatography. On SDS-polyacrylamide gel electrophoresis under reduction, purified TF apoprotein gave two major protein bands corresponding to molecular weights of 53 and 34 to 36 KD. The identity of these forms of TF was confirmed by Western blotting using a polyclonal antibody against human brain TF. Under reduction, the TF antibody bound with a monomeric form of TF (53 KD), and without reduction, to several forms of TF (34 to 128 KD). Preliminary carbohydrate analysis suggested that TF is a glycoprotein and contains about 22% total carbohydrates. The coagulant activity of the purified apoprotein was reconstituted by the addition of phospholipids. The effects of varying concentrations (0 to 8 &mu;g) of polyclonal antibodies to TF and FVII on TF procoagulant activity were studied. Both antibodies inhibited more than 70% of the procoagulant activity of TF in an FX activation assay. The complex formation between purified TF apoprotein and FVlla was demonstrated by using an enzyme-linked immunosorbent assay. TF formed a complex with FVIIa in a concentration-dependent and saturable manner. We conclude that in human melanoma cells, TF occurs in monomeric and heterodimeric forms and appears to have similar properties as reported for TF from other sources. Key Words: Melanoma cells-Tissue factor&mdash;Immunoaffinity purification&mdash;TF-FVII ELISA.
Tissue factor (TF) is an integral membrane glycoprotein 47 to 53 KD in size that, when assembled with factor Vlla (FVIIa), initiates coagulation. The TF'-F'~'I~~ complex is the main initiator of the coagulation cascade via activation of factors IX and X ( l ~, thereby resulting in thrombin production. Tissue factor is expressed on the surface of various cells including endothelial cells, fibroblasts, monocytes, and monocytelike cell lines (2) . Several tumors express constitutively (3) (4) (5) (6) , frequently shedding microvesicles carrying TF. The tendency to thrombotic complications in various cancers is probably at least partly dependent on this increased cellular procoagulant activity. There is also evidence that TF is involved in metastasis (7) and angiogenesis in tumors (8) . TF is synthesized as a 295-amino-acid polypeptide in-eluding a leader sequence. In its mature form, TF consists of a 263 amino acids organized into a 219-aminoacid extracellular domain, a 23-amino-acid transmembrane segment, and a 21-amino-acid cytoplasmic tail (9) . The molecular structure of TF indicates that it may be classified in the class 2 cytokine receptor family, which includes the receptors of interferon-a, -0, and -y (10).
Purification of TF has been reported from human brain and placenta (11) (12) (13) (14) (15) . However, no attempts have been made to purify and characterize TF from human mai~gnant melanoma cells. Here, we report for the first time the purification and some properties of tissue factor from human A375 malignant melanoma cells.
MATERIALS AND METHODS

Materials
Cyanogen bromide-activated Sepharose-4B was purchased from Pharmacia Fine Chemicals (Uppsala, Swe-den). Precast sodium dodecyl sulfate (SDS)-~I yaerylamide' ~el;~ were obtained from ~dave~ (San Diego, ~A,~* Low-molecular-weight protein markers (phosphorylase b, bovine serum ~i~u~nin, c~v~lb~~nin, ' carbonic anhydrase, and soybean trypsin inhibitor) and blot-adsorbent filter paper were supplied by Bio-Rad Laboratories (Richmond, CA). Polyvinylidene ~i~.~uc~~de (PVDF) membranes and Centricon-10 concentrators were obtained from Millipore Corp. (Bedford, MA). Purified polyclonal antibody against human brain TF and chromogenic substrate for factor Xa (Spectrozyme) were from American Diagnostica, Inc. (Greenwich, CT). Nonlipidated recombinant human tissue factor and monoclonal antibody (H36) against it was a gift from Sunol Mo-' lecular Corp. (Miramar, FL Identification c~~ malignant cell tissue factor TF expression on human malignant A375 melanoma cells was analyzed by immunofluorescence using an EP-ICS Elite ESP flow cytometer (Coulter Electronics, Hialeah, FL). Human A375 malignant melanoma cells (I x 10&dquo;/ mL) were incubated with monoclonal TF antibody (H36, 10 >g/mL) or with isotype control IgG (10 lkg/mL) for 45 minutes, on ice, washed in phosphatebuffered saline (PBS) and incubated in Oregon Greenconjugated anti-mouse IgG (10 u.g/mL) for an additional 45 minutes on ice. Cells were washed and resuspended in ' 400 ~~ of PBS before analysis. Mean channel fluorescence intensity determined for each sample. 1'~~pa~~t~c~~ of ~~a ~ immunpadsorbent affinity column Purified antibody against human brain tissue factor was. used in the preparation an immunoaffinity column. Briefly, TF antibody (2 mg/mL) was dissolved and dialyzed overnight at 4°C against coupling buffer (0.2M ' 3a~Gt33, 0.5M I~Fa~I, pH 8.0) and coupled with 5.0 mL of CNBr-activated Sepharose-4B for 2 hours at room temperature and for 72 hours at 4'C by end-over-end rotation. Unbound antibody was removed by washing the gel three times in coupling buffer. Unreactive sites were blocked in 0.1 M '~'ri~-~-I~I, pH 8.0 for 2 hours at room temperature. Finally, the gel was washed in five cycles of alternating pH buffers of 0. 1 M acetate, 0.5M NaG!. pH 4.0, and Q. I M Tris-HCI, ~?.~1~ NaCl, pH 8.~. ' Immunoadsorbent gel was stored in Tris-satine (50 mM Tris, 100 rnMl)faCl),pH7.5, containing 0.02% NaN3 at 4°C. urr~~ataun of tissue factor from human melanoma cells Tissue factor was purified from human melanoma cells (ATCC, Rockville, MD), using immunoaffinity chromatography. Melanoma (A375) cells were cultured in I,fi4~ RPMI containing 10% fetal bovine serum and antibiotics for 48 to 72 hours as published (16) . Cells (5 to 7 x 10~/mL) were washed three times in PBS and solubilized in 25 mM Tris-HCI, pH 7.5 containing l'.O~In Triton X-100, 200 >M PMSF, and Of.LM leupeptin for 16 hours at 4°C. Complete lysis of the cells was determined by microscopic examination and the cell debris was removed by centrifugation at ?&dquo;l,fl()(l ~ ~; for 30 minutes. Triton X 100 ~c~inbili~ed melanoma cell lysate was applied to a immunoadsorbant column (1.0 x 5.0 cm), equilibrated in 50 mM Tri~;-H~:1, 100 mM Nacl, pH 7.5, 1 00 ~LM PMSF, I .fl RM leupeptin, and 0.0?% I~IaI~i3
Tris.-saline): The column was closed for 2 hours at room temperature, and for I6 hours at 4'C. It was washed with Tris-saline buffer at 4°C until the absorbance at 280 nm became zero. Tissue factor apoprotein was eluted in 0.1 M Gly-HCI buffer at pH 2.5, tOO RM PMSF, 1.0 VLM leupeptin, and 0.02% NaN3. Fractions under this peak were combined, pH adjusted to 7.5 by the addition of 1.0 M Tris base, and concentrated using Centricon-10. Purified TF apoprotein was stored at -80°C.
Protein determination
Protein concentration was determined according to the method of Bradford I'~) using BSA as the standard. For monitoring the column fractions, absorbance at 280 nm was used.
SDS-polyacrylamide gel electrophoresis of TF
Pc~I~acryli~mide gel electrophoresis of melanoma cell purified TF apoprotein in the presence of SDS was performed according to the method of Laemmli (18) ) Tissue factor assay . One-stage clotting assay ) TF procoagulant activity was measured using normal ) human pooled plasma and CaC'2 in a Sonoclot 11 surgical j analyzer (Model i~P2951 ~ Sienco, Inc., Morrison, CO) as previously described (19) .
Two-step TF assay j
The amidolytic activity of TF was measured in a two-) step factor X-activation assay as reported (20) . Briefly, ; relipidated TF (25 to 50 ng) in Tris-saline buffer, pH 7.5, 1 was incubated with FVIIa (5 ng) and CaC'2 ( i Immunoblotting of tissue factor 1 ' Immunoblotting of melanoma cell purified TF apopro-! tein was carried out according to our standard procedure I ~~ l }, with modifications. Purified TF (2.0 j~g/lane) under I both reducing and nonreducing conditions and molecular ! weight markers were electrophoresed on an 4 to 15% I SDS-polyacrylamide slab gel according to the method of I Laemmli (18) . The pc~Iyp~ptides were transferred elec-I trophoretically to polyvinylidene difluoride (PVDF) ' I membrane for 90 minutes at 100 mA. Immediately after I transfer, the molecular weight marker strip was cut and i stained in Coomassie blue R-250 for I hour, and the rest ! of the PVDF membrane was soaked in 50 mL of 5% i BSA in lOmM Tri~-~Cl, pH 7.5, 0.9% I~IaCI (Tris-) saline), and incubated at room temperature for I hour on I I a rocking platform. The membrane was then incubated ! with purified polyclonal antibody (IgG fraction) against i ¡ human brain TF, diluted with 5% BSA in Trips-saltine I (antibody concentration 3 pg/mL), for I hour at room : temperature and 16 hours at 4'C. The membrane was ! then washed four times, each for 20 minutes, in Trisi saline containing 0.05% Tween-20. It was then imi mersed in fresh 5°~~ BSA Tris-saline containing antij rabbit IgG, alkaline phosphatase conjugated (1:1,000 dilution), and incubated for 2 hours at room temperature, ' before washing as above. Alkaline phosphatase color was developed using BCIP/ NBT as a substrate for 2 minutes at room temperature.
Effect '~f TF anybody on FX-activating activity of melanoma ~c~ll TF The effect of varying concentrations of polyclonal antibody to TF was studied on the factor X-activating activity of TF. Briefly, different concentrations (0 to 8.0 ,g) of purified polyclonal antibody to human brain TF were preincubated, with the purified lipidated TF (50 ng) from human A375 melanoma cells, for 1 hour at 37°C.
The factor X-activating activity of TF was determined as described above.
Effect of FVII antibody on TF-FVII complex formation A purified polyclonal antibody to human FVII was used to study its effect on TF-FVII complex formation. Different concentrations (0 to 0.8 pg) of the antibody were preincubated with human FVIIa (5 ng) for I our at 37°C, followed by the addition of purified TF (50 ng) and CaCI2 (5 mM) . TF activity was determined in a two-step FX activation assay.
Demonstration of TF-FYII complex format;on by enzyme-linked immunosorbent assay
The assay was performed according to our published procedure (22) , with modifications. Microtitration plates were coated with the melanoma cell purified TF apoprotein (0.5 tol.O u<g/mL) and rabbit brain thromboplastin (2 ,,~lm~, control) in bicarbonate coating buffer (15 mM I~~~~t~~, 35 mM NaI~CU3, pH 9.6, 0.02tll 1'~T~t~I~) for 3 hours at 3'7'~C and for 16 hours at 4°C. The wells were washed five times in Tris-saline Tween buffer (1 OmM Tris-HCI, 0.9% NaCI, 0.05% Tween-20, pH 7.5). Varying amounts (0.1 to 0.6 pg mL) of purified activated FVII in 200 pJL of Tris-saline buffer, pH7.5, containing 5 mM CaC'2 was added to each coated well for l hour at 37°C. The washing procedure was repeated as before to remove the unbound <FVUa. Two hundred microliters of anti-human FVII antibody (20 >g/mL) in Trissaline buffer was added to each well and incubated for 1 hour at 37°C. Wells were washed as above, and 200 ~L of alkaline-phosphatase conjugated anti-sheep IgG (l : 1 ,000 dilution), was added to each well for 2 hours at 37°C and 16 hours at 4'C. After washing, 200 p;L of p-mtrophenyl phosphate (1.0 mg/mL) in 0.1 M Gly-HCI bluffer, pH 10.4, containing ImM MgC'2 was added to each well. After 5 minutes at room temperature, color development was stopped by the addition of 50 RL of 3 N ~~tJH to each well. The color intensity was read at 405 nm against a substrate blank. The formation of the complex between TF and FVIIa was expressed as the bound alkaline phosphatase activity at 405 nm/5 minutes.
RESULTS
/.
~ : Identification ar~ tissue factor ~on human A375 melanoma cells Human A375 malignant melanoma cells were analyzed for TF expression using mt~nc~c3~r~a~ antibody against recombinant human TF. As shown in Figure 1 , a significant amount of TF was detected on the surface of ' the melanoma cells by flow cytometry.
Immuno~~nity purification of tissue factor
Tissue factor was purified from human malignant melanoma cells by Triton X-100 extraction and immunoaffinity chromatography. Table shows the different steps involved in the purification. The results show a 2,000-fold purification of tissue factor apoprotein with specific activity of 129,733 U/mg of protein (Table 1 ). Parity and ~mmmun~ahlc~~tir~~ of tissue factor The purity of TF was assessed on 4 to 1 5Th SDSpolyacrylamide gel electrophoresis. With reduction, purified TF apoprotein gave two major and one minor protein bands corresponding to molecular weights of 53, 36, and 29 KD, respectively ( Fig. 2A ). tmmunob!otting of purified TF was carried out under both reducing and nonreducing conditions usinc, polyclonii antibody to human brain TF. As shown in Figure 2B , TF antibody bound with a 53-KD band of TF under reducing conditions and with multiple forms of TF without reduction (34 to I~8 KD). To rule out any contamination o~ FVII, A375 melanoma cells (1 x 106/mL) were incubated with a monoclonal antibody to human recombinantTF (10 pg/mL) or isotype control antibody (mouae !gG1, 10 p §/mL) for 45 minutes on ice. Cell surface-expres$ed TF antigen was determined as described in the Materials and Methods section. Binding of TF antibody to A375 cells is shown by the shaded histogram and the binding of isoJype control antibody by the line histogram. We studied the effect of varying concentrations (0 to 8 :~) of purified polydonal antibody against human brain TF on the FX-activating activity of purified TF. As shown in Figure 3 , more than 70% of TF activity was inhibited at an antibody concentration oaf 2 }jLg. No further increase in inhibition was noted by increasing the antibody concentration as high as 8.0 pg.
Effect of FVII antibody on TF-FVII complex formation
The effect of different concentrations (0 to 8 Rg) of human FVII antibody was determined on the TF-FVII Effect of human brain tissue factor (TF) antibody on melanoma cell purified TF activity. Varying concentrations (0 to 8 pg) of purified polyclonal TF antibody was preincubated with the fixed amount of TF (50 ng) for 1 hour at 37°C. Unneutralized TF activity was determined in a factor X (FX) activation assay. complex formation. At an antibody concentration of 8 jig almost 80% of the complex formation between TF-FVII was inhibited, as assessed by the FX activation assay ; Fi~. 4). B i n d i n g of human FVII~a to the TF apoprotein coated on the polystyrene surface An enzyme-linked immunosorbent assay was used to determine whether melanoma cell purified TF forms a complex with PVHa. TF apoprotein at varying concentrations (0.5 and 1.0 Rg/mL) and rabbit thromboplastin (2.0 {jLg/mL, positive control) were coated directly on the wells of a plastic microtiter plate. Increasing amounts of purified FVIIa in the presence of CaC12 was added. The complex formed between TF and FVIIa was detected by FVII antibody, followed by alkaline phosphataseconjugated secondary antibody and the enzyme substrate. The extent of the complex formation between fluid-phase IIa and'adsc~rbed ~'F was detected by the enzymatic activity of the bound alkaline phosphatase (Fig. 5 Nonspecific binding of FVHA was studied by using v ing concentrations of FVlla without TF (Fig. 5 ).
DISCUSSION
Cancer patients generally have an ongoing, persistent intravascular coagulation, possibly due to overproduction of TF by tumor cells. The tendency to thrombotic complications in various cancers is probably at least partly dependent on the procoagulant activity of tumor cells. We (16, 19) and others (23) have confirmed that : most tumor cells have an increased level of TF and that this is responsible for their procoagulant activity.
Although purification off TF has been reported from normal tissues such as human brain and placenta ~~ l1 5), no attempts have been made to purify tissue factor from human malignant melanoma cells. This describes the purification and some properties of TF from human malignant melanoma cells. Using flow cytometry, TF antigen was demonstrated on human A375 malignant melanoma cells (Fig. I ) .' Further, a simple and rapid immunoaffinity method was developed to purify melanoma cell TF. TF apoprotein was purified more than 2,000-fold from cell lysate ( Table 1 ). Purified TF apoprotein on SDS-polyacrylamide gel electrophoresis under reduction gave two major and a minor protein band corresponding to molecular weights of 53, 36, and 29 KD, respectively ( Fig. 2A ). The molecular weight of TF from human brain and placenta has been reported to ran~~ ~'rc~~n ~.~ tt~ ~3 I~I) ~l I-1~~.'Th~ ider~tity o~mul~rple range from 43 to 53 kD (11) (12) (13) (14) . The identity of multiple forms of melanoma cell TF was confirmed in immunoblotting using polydonal antibody to human brain TF. Under reduction, this antibody bound with a monomeric form of TF (53 KD), and without reduction, to several forms (34 to 128 KD, Figure 2B ). Morrissey et al. (!5) have reported that human brain TF exists in monomeric (47 KD) and heterodimeric (58 KD) forms, with the latter form apparently being a disulfide-linked heterodimer composed of TF and the alpha chain of hemoglobin. We recently demonstrated that purified TF apoprotein from human A375 malignant melanoma cells forms a specific complex with hemoglobin (20) . This interaction enhanced the procoagulant activity of TF (24) .
Tissue factor is a lipoprotcin cofactor that markedly enhances the catalytic activity of blood coagulation factor Vlla towards its substrates. Phosphatidyl serine has been proposed as a regulator of TF procoagulant activity FIG. 4 . Effect of factor IJIf ~FVii) antibody on tissue factor (TF)-FVII complex formation. Different concentrations (0 to 8 pg) of human FVII.specific potycfona! antibody was preincubated with a fixed amount of FVlla (5 ng), for 1' hour at 37°C, followed by the addition of purified TF (50 ng) and CaC'2 (5 mM). TF activity was determined in a two-step FX activation assay.
FIG. 5. Enzyme-linkedin'Bl'I1unosotbentassay
detection of tissue factor (TF)-factor VII (FVII) complex formation. Melan9rnaçeUpurified TF at two concentrations (0.5 and 1.0 pg/mL) and rabbit brain thromboplastin (2.0 ug/mL, as a control) in coating buffer were applied to plastic wells for 3 hours at 37'C and for 16 hours at 4&dquo;C. After washing with Tris-satine-Tween buffer, pfi~fi 7.~, varying amounts of purified activated FVII in the presence of CaC12 (5mM) were added for 1 hour at 37°C. Wells were washed and anti-human FVfiI psafiy~lc~nafi ~ntibotfy ~~(t fi-~~tmt} in 'Trfis-~~fiin~ ' polyclonal antibody (20 pg/mL) in Tris-saline buffer was added for 1 hour at 37°C. After washing, alkaline phosphatase-conjugated secondary antibody was added for 2 hours at 37°C and for 16 hours at ~.~'~. Wells were washed as above and the alkaline phosphatase color developed using p-nitropheny! phosphate as a substrate. The compfieu formation was expressed as the enzymatic activity of the bound afik~line~ phosphatase. on cell surfaces (25) . The purified melanoma cell TF apoprotein required CaC'2 and PS/PC (30:70), for the ' expression of its procoagulant and FX-activating activity. The effects of varying concentrations (0 to 8 pg) of polyclonal antibodies to human TF and FVII on TF activity were studied. Both antibodies inhibited more than 70% off the procoagulant activity of purified TF in a FX-activating assay (Figs. 3 and 4 ). This suggests that human brain and melanoma cell TF are antig~r~i~;a~ly similar. To further characterize the malignant cell TF, we studied the complex formation between TF apoprotein and FVlla, using an enzyme-linked immunosorbent assay. Purified TF formed a complex with FVlla in a concentration-dependent and saturable manner (Fig. 5 ).
Tissue factor plays an important role in hemostasis, but is being increasing recognized to have noncoagulant functions, especially in tumor cell adhesion (26) , metastasis (7) , and angiogenesis (8) . Because aberrant TF expression in vivo is responsible for life-threatening thrombotic complications associated with septic shock, cancer, and atherosclerosis. (27) (28) (29) , complete understanding of its structure-function relationship and cellular regulation is crucial.
In conclusion, we have purified TF from human A375 malignant melanoma cells for the first time and shown that it occurs in monomeic and heterodimeric forms.
The purified melanoma cell TF appears to have similar properties as reported for TF from other sources.
.
